The news: Rippl, a Seattle startup focused on the mental health of seniors, launched Wednesday with $32 million in seed funding. The company is developing a care program focused on… Read More
ARCH Venture Partners has closed a $2.975 billion fund targeted for early-stage biotech companies. The firm’s 12th venture fund comes on the heels of a nearly $2 billion fund announced… Read More
When Juno Therapeutics launched in 2013, cell therapy was a nascent field. Early clinical studies were showing dramatic rates of remissions in leukemia patients treated with their own immune cells,… Read More
When a patient is bedridden during a hospital stay, they can lose muscle mass at a rapid clip, compounding problems from their original illness. But what if there was a… Read More
Seattle-based startup Rodeo Therapeutics is raising more cash for its work on tissue repair and regeneration. The company has reeled in another $4.3 million, according to a new regulatory filing,… Read More
Former Juno Therapeutics executives Hans Bishop and Steve Harr have launched Sana Biotechnology, a startup focused on cell therapy, gene therapy and gene editing. Backed by ARCH Venture Partners, Flagship… Read More
Seventeen years after founding the Institute for Systems Biology (ISB), spurring the creation of systems biology as a field, genomics and biotechnology pioneer Lee Hood is stepping down as its… Read More
Robert Nelsen may not be a household name in venture capital circles — certainly not the way that Reid Hoffman, John Doerr and Fred Wilson are known. But the Seattle… Read More